Reset filters
8 June 2026

Presented at Genetics-inspired Therapeutics for PH by Lars Harbaum, Universitätsklinikum Hamburg-Eppendorf

Congresses & Symposia
5 June 2026

A001 Targeting ZIP12 to Modulate Intracellular Zinc and Vascular Dysfunction in Pulmonary Arterial Hypertension, A002 Role of The Protein Ttk in the Vascular Remodeling Processes in Pulmonary Artery Hyerpenstion and more.

Pulmonary Circulation
4 June 2026

Ventilatory inefficiency, assessed by the VE/VCO2 slope during cardiopulmonary exercise testing (CPET), is a key physiological marker. However, differences in ventilatory efficiency between chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), as well as their response to treatment, remain incompletely characterized.

Pulmonary Circulation
4 June 2026

Pulmonary hypertension (PH) is frequently accompanied by a decline in kidney function. In this retrospective cohort, worsening PH was associated with long-term eGFR decline only when accompanied by transition from acute kidney injury (AKI) to acute kidney disease (AKD), defined as persistent kidney dysfunction beyond 7 days after AKI onset, whereas early AKI reversal was not.

Pulmonary Circulation
28 May 2026

In this PH Community Call, we discussed: 

  • Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit
    Sotatercept improves small airway disease and hyperinflation in patients with pulmonary hypertension
Community Calls
26 May 2026

Catheter-directed thrombolysis (CDL) and mechanical thrombectomy (MT) are increasingly used for intermediate–high–risk pulmonary embolism (PE), yet comparative long-term outcomes remain uncertain. We aimed to compare the effectiveness and safety of CDL versus MT in real-world clinical practice.

Pulmonary Circulation